Temporary pacemakers are typically used for at least 24 hours before care teams consider implanting a permanent device. New research out of Canada suggests it may make sense in certain scenarios to go straight to the permanent pacemaker. 

The European Society of Cardiology 2025 congress includes 10 Hot Line sessions and 28 late-breaking science sessions to showcase the latest science.

Giving colchicine to patients prior to TAVR may reduce the risk of certain conduction disturbances, according to new research published in the Journal of the American Heart Association. It does not, however, improve survival.

Researchers had thought 2-HOBA might reduce the risk of AFib recurrence after catheter ablation procedures. What they found, however, was that treatment with the compound was actually harmful for patients instead of helpful. 

John Puskas, MD, chief of cardiothoracic surgery at Emory University Hospital Midtown, noted that both treatment options have their own benefits. It often depends on the patient's age and comorbidities, though there are other factors to consider as well. 

Cardiovascular-kidney-metabolic (CKM) syndrome is a popular research topic among cardiologists, highlighting just how closely obesity, type 2 diabetes, chronic kidney disease and cardiovascular disease are related to one another. Joshua Joseph, MD, spoke to Cardiovascular Business about this ongoing trend.

Shockwave Medical, now a part of Johnson & Johnson MedTech, has consistently been found safe for patients. However, many previous clinical trials excluded high-risk patients, making it important to track real-world outcomes as time goes on.

In fact, more than 55% of all PCI cases in 2022 were performed using radial access. Cardiologists are sure to be keeping a close eye on this trend as time goes on.